Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome

Yonsei University1,000 enrolled

Overview

Developing a molecular genetic test that can identify prognostic factors which can predict response to treatment, and to contribute to the establishment of future therapeutic strategies base on prognostic factors by undergoing peripheral blood and bone marrow examination of Myelodysplastic Syndrome (MDS) patients at diagnosis and relapse.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Myelodysplastic Syndrome

Interventions

No interventionOTHER

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MDS diagnosed by bone marrow aspiration and biopsy at Severance Hospital. * Male and Female over 16 years of age. ③ Written consent of the patient to participate in the cohort ④ Deaths during the study period are waiver of consent Exclusion Criteria: ① Refusal or trouble understanding the written consent

Locations (1)

Severance Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

the number of patients with MDS to examine new prognostic factors

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.